Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.11% Nasdaq Up0.35%

Cumberland Pharmaceuticals, Inc. (CPIX)

4.46 Down 0.01(0.22%) 2:29PM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Cumberland Pharmaceuticals, Inc.
2525 West End Avenue
Suite 950
Nashville, TN 37203
United States - Map
Phone: 615-255-0068
Fax: 615-255-0094

Index Membership:N/A
Industry:Drug Manufacturers - Other
Full Time Employees:96

Business Summary 

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Cumberland Pharmaceuticals, Inc.

Corporate Governance 
Cumberland Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 4; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. A. J. Kazimi MBA, 56
Founder, Chairman, Chief Exec. Officer and Pres
Mr. Richard S. Greene , 49
Chief Financial Officer, Principal Accounting Officer and VP
Mr. Leo Pavliv R.Ph., 53
Chief Devel. Officer and Sr. VP of Operations
Mr. James L. Herman , 59
Chief Compliance Officer and VP of National Accounts
Mr. Martin E. Cearnal , 69
Chief Commercial Officer, Sr. VP and Director
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders